Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?

Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan ...

University of Osaka researchers used genome editing to program mouse liver cells to produce exenatide, a weight-loss drug.

Adults with type 1 diabetes on multiple daily injection therapy saw no benefit in glycemic measures when adding on preprandial injections of short-acting exenatide, according to findings from a ...

Exenatide is the active ingredient in BYETTA(R) (exenatide) injection, which is currently available in the U.S. and in many countries worldwide for people with type 2 diabetes who are unable to ...

Exenatide is a GLP-1-like (analog) medication primarily prescribed to treat Type 2 diabetes, approved by the U.S. Food and Drug Administration in 2005.

Exenatide, or Byetta, is a synthetic peptide that acts at the receptor for GLP-1 – a hormone that is made in the gastrointestinal track that stimulates insulin secretion and also decreases the ...

A once-weekly, injectable, extended-release formulation of exenatide, an exendin-4–based GLP-1 receptor agonist approved for the treatment of type 2 diabetes, has been shown to lower blood ...

Exenatide, the first drug in the new class of incretin mimetics, will be available to pharmacies by June 1 in both a 5- and a 10-μg per dose prefilled pen-injector device.

Exenatide, an incretin mimetic, was approved by the Food and Drug Administration (FDA) on April 28, 2005, as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus.

The FDA approved exenatide in April 2005 and it was the first incretin mimetic to hit the market. Exenatide (Byetta, Amylin) is synthetic exendin-4, which binds to and activates the pancreatic ...